Insider Selling: Retrophin Inc (RTRX) SVP Sells 1,050 Shares of Stock

Share on StockTwits

Retrophin Inc (NASDAQ:RTRX) SVP Elizabeth E. Reed sold 1,050 shares of the business’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $17.73, for a total transaction of $18,616.50. Following the sale, the senior vice president now directly owns 20,033 shares of the company’s stock, valued at approximately $355,185.09. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

NASDAQ RTRX traded up $0.44 during trading hours on Friday, hitting $19.01. 412,622 shares of the company’s stock traded hands, compared to its average volume of 373,252. Retrophin Inc has a 52-week low of $17.53 and a 52-week high of $33.00. The stock has a market cap of $769.48 million, a PE ratio of -7.48 and a beta of 0.91. The company has a current ratio of 4.57, a quick ratio of 4.52 and a debt-to-equity ratio of 0.69.

Retrophin (NASDAQ:RTRX) last announced its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.41). The business had revenue of $39.57 million for the quarter, compared to analysts’ expectations of $41.40 million. Retrophin had a negative net margin of 75.75% and a negative return on equity of 41.38%. The firm’s revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.14) EPS. On average, sell-side analysts forecast that Retrophin Inc will post -3.02 EPS for the current fiscal year.

A number of analysts have recently commented on RTRX shares. ValuEngine cut shares of Retrophin from a “buy” rating to a “hold” rating in a research note on Thursday, April 18th. TheStreet cut shares of Retrophin from a “c-” rating to a “d+” rating in a research note on Friday, February 22nd. Barclays assumed coverage on shares of Retrophin in a research note on Monday, April 22nd. They set an “overweight” rating and a $36.00 target price for the company. William Blair reaffirmed an “outperform” rating on shares of Retrophin in a research note on Wednesday, April 17th. Finally, BidaskClub cut shares of Retrophin from a “hold” rating to a “sell” rating in a research note on Thursday, April 4th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. Retrophin has a consensus rating of “Hold” and a consensus price target of $45.67.

A number of large investors have recently bought and sold shares of RTRX. AQR Capital Management LLC increased its position in shares of Retrophin by 117.5% during the third quarter. AQR Capital Management LLC now owns 29,132 shares of the biopharmaceutical company’s stock worth $837,000 after acquiring an additional 15,740 shares during the period. Legal & General Group Plc increased its position in shares of Retrophin by 33.5% during the third quarter. Legal & General Group Plc now owns 13,541 shares of the biopharmaceutical company’s stock worth $389,000 after acquiring an additional 3,395 shares during the period. Vanguard Group Inc. increased its position in shares of Retrophin by 1.4% during the third quarter. Vanguard Group Inc. now owns 1,928,602 shares of the biopharmaceutical company’s stock worth $55,409,000 after acquiring an additional 26,016 shares during the period. Federated Investors Inc. PA increased its position in shares of Retrophin by 4.3% during the third quarter. Federated Investors Inc. PA now owns 93,495 shares of the biopharmaceutical company’s stock worth $2,686,000 after acquiring an additional 3,855 shares during the period. Finally, Vanguard Group Inc increased its position in shares of Retrophin by 1.4% during the third quarter. Vanguard Group Inc now owns 1,928,602 shares of the biopharmaceutical company’s stock worth $55,409,000 after acquiring an additional 26,016 shares during the period.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Retrophin Inc (RTRX) SVP Sells 1,050 Shares of Stock” was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/4344769/insider-selling-retrophin-inc-rtrx-svp-sells-1050-shares-of-stock.html.

Retrophin Company Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Featured Article: Dividend Achievers

Insider Buying and Selling by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

MKM Partners Lowers ADTRAN  Price Target to $17.00
MKM Partners Lowers ADTRAN Price Target to $17.00
Apple  PT Raised to $180.00 at Nomura
Apple PT Raised to $180.00 at Nomura
Advaxis  Lowered to “Hold” at ValuEngine
Advaxis Lowered to “Hold” at ValuEngine
Zacks Investment Research Upgrades Atlas Air Worldwide  to “Hold”
Zacks Investment Research Upgrades Atlas Air Worldwide to “Hold”
Apple  Raised to “Outperform” at Raymond James
Apple Raised to “Outperform” at Raymond James
Zacks Investment Research Lowers Agilysys  to Hold
Zacks Investment Research Lowers Agilysys to Hold


© 2006-2019 Ticker Report